AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.

臺大醫院-腫瘤醫學部;臺大醫學院-腫瘤醫學研究所;臺大醫學院-癌症研究中心;Ramalingam, Suresh S.Suresh S.RamalingamYang, James Chih-HsinJames Chih-HsinYangLee, Chee KhoonChee KhoonLeeKurata, TakayasuTakayasuKurataKim, Dong-WanDong-WanKimJohn, ThomasThomasJohnNogami, NaoyukiNaoyukiNogamiOhe, YuichiroYuichiroOheRukazenkov, YuriYuriRukazenkovFrewer, PaulPaulFrewerCantarini, MireilleMireilleCantariniGhiorghiu, SerbanSerbanGhiorghiuJanne, Pasi A.Pasi A.Janne2017-06-272018-07-092017-06-272018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/280168[SDGs]SDG3AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.